Adial Pharmaceuticals: Funding, Investors & Team (Oct 2026)
Adial Pharmaceuticals is a biopharmaceutical business in the clinical stages that specialises on the creation of addiction treatments. The Company's lead investigational new drug product, AD04, is being studied in the Company's historic ONWARDTM Phase 3 clinical trial for the potential treatment of AUD in subjects with specific target genotypes, which are to be identified using the Company's proprietary companion diagnostic genetic test. AD04 is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD). There were no overt safety concerns in a Phase 2b clinical trial using AD04 for the treatment of AUD, however there were encouraging outcomes in terms of lowering frequency of drinking, quantity of drinking, and heavy drinking (all with statistical significance) (there were no statistically significant serious adverse events reported)
Adial Pharmaceuticals has raised $47.8M across 4 funding rounds on record, the most recent an undisclosed round of $32.0M announced in Jun 2026.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Adial Pharmaceuticals Company Profile and Key Stats
Latest funding round on record: Jun 2026.
Adial Pharmaceuticals Funding Rounds
Adial Pharmaceuticals raised $5.0M in a Post-IPO Equity announced in Jul 2021.
7 months later, a Post-IPO Equity of $10.0M was announced in Feb 2022.
1 years later, an undisclosed round of $750k was announced in Feb 2023.
3.3 years later, an undisclosed round of $32.0M was announced in Jun 2026.
Adial Pharmaceuticals Founders and Leadership Team
Contact details for the Adial Pharmaceuticals team: 2 of 2 have an email address on file.
Start 14-day free trial →Adial Pharmaceuticals Funding Compared to Other Biotechnology Startups
Adial Pharmaceuticals' latest round of $32.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Adial Pharmaceuticals in Biotechnology and Charlottesville
Companies Similar to Adial Pharmaceuticals
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Adial Pharmaceuticals Funding FAQs
What does Adial Pharmaceuticals do?
Adial Pharmaceuticals is a biopharmaceutical business in the clinical stages that specialises on the creation of addiction treatments. The Company's lead investigational new drug product, AD04, is being studied in the Company's historic ONWARDTM Phase 3 clinical trial for the potential treatment of AUD in subjects with specific target genotypes, which are to be identified using the Company's proprietary companion diagnostic genetic test. AD04 is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD). There were no overt safety concerns in a Phase 2b clinical trial using AD04 for the treatment of AUD, however there were encouraging outcomes in terms of lowering frequency of drinking, quantity of drinking, and heavy drinking (all with statistical significance) (there were no statistically significant serious adverse events reported)
How much funding has Adial Pharmaceuticals raised?
Adial Pharmaceuticals has raised $47.8M across 4 rounds on record. The most recent is an undisclosed round of $32.0M announced in Jun 2026.
When did Adial Pharmaceuticals last raise funding?
Adial Pharmaceuticals' most recent funding round on record is an undisclosed round of $32.0M, announced in Jun 2026.
Who founded Adial Pharmaceuticals?
FundedIQ lists Cary Claiborne (Founder) at Adial Pharmaceuticals.
Who is the CEO of Adial Pharmaceuticals?
William Stilley is listed as CEO at Adial Pharmaceuticals.
Where is Adial Pharmaceuticals headquartered?
Adial Pharmaceuticals is based in Charlottesville, Virginia, United States.
How many employees does Adial Pharmaceuticals have?
Adial Pharmaceuticals is in the 11-50 employee band.
How does Adial Pharmaceuticals' funding compare to other Biotechnology startups?
Adial Pharmaceuticals' latest round of $32.0M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Adial Pharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Adial Pharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.